Immuneering Co. (NASDAQ:IMRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Immuneering Co. (NASDAQ:IMRX) have received an average rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $12.80.

A number of research firms have weighed in on IMRX. Chardan Capital restated a “buy” rating and issued a $13.00 price target on shares of Immuneering in a research note on Wednesday, November 20th. Needham & Company LLC restated a “buy” rating and set a $15.00 target price on shares of Immuneering in a research note on Thursday, November 14th.

Immuneering Price Performance

IMRX stock opened at $2.05 on Wednesday. The business’s 50-day moving average is $2.21 and its two-hundred day moving average is $1.63. The firm has a market capitalization of $63.65 million, a P/E ratio of -1.04 and a beta of -0.40. Immuneering has a 1 year low of $1.00 and a 1 year high of $8.89.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new position in Immuneering during the 2nd quarter worth approximately $492,000. Renaissance Technologies LLC purchased a new stake in shares of Immuneering in the second quarter valued at approximately $447,000. Vanguard Group Inc. grew its holdings in Immuneering by 12.1% during the first quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after acquiring an additional 129,851 shares during the period. Acadian Asset Management LLC purchased a new position in Immuneering in the second quarter worth $67,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Immuneering in the second quarter valued at $44,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.